SRL
PTGX icon

Scientech Research LLC’s Protagonist Therapeutics PTGX Stock Holding History

Scientech Research LLC’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,271
Closed -$884K – 805
2025
Q1 		$884K Buy
18,271
+6,217
+52% +$261K 0.23% 164
2024
Q4 		$465K Sell
12,054
-2,473
-17% -$108K 0.13% 317
2024
Q3 		$654K Buy
+14,527
New +$587K 0.13% 307

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scientech Research LLC's PTGX Position: Q2 2025 in Review

Scientech Research LLC sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 18,271 shares — an estimated $884K sold.

Scientech Research LLC first reported a position in PTGX in Q3 2024 and held it in 3 quarters. The position peaked at $884K in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Scientech Research LLC reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Scientech Research LLC sold 18,271 Protagonist Therapeutics shares in Q2 2025, an estimated $884K.
  • Scientech Research LLC first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 3 quarters.
  • Scientech Research LLC's Protagonist Therapeutics position peaked at $884K in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Scientech Research LLC's 13F filing for Q2 2025, filed 14 Aug 2025.